SCHEMBL9718359

SCHEMBL9718359

CC/C=C/C(C)(C)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.35
CYP19A1 P11511 4/20 0.35
MAPT P10636 4/20 0.35
PPARG P37231 3/20 0.35
OXER1 Q8TDS5 3/20 0.35
RXRA P19793 2/20 0.35
FFAR1 O14842 2/20 0.35
TSHR P16473 2/20 0.35
ACLY P53396 1/20 0.34
F7 P08709 3/20 0.33
F3 P13726 3/20 0.33
PPARA Q07869 3/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C19 P33261 2/20 0.33
PTGS1 P23219 2/20 0.33
KMT2A Q03164 2/20 0.33
PPARD Q03181 2/20 0.33
HIF1A Q16665 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CYP3A4 P08684 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9718363 1.00 ALDH1A1 (0.35) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL19276329 0.80 TSHR (0.35) ALDH1A1TSHRACLYCYP2D6CYP2C19
SCHEMBL18203203 0.80 ALDH1A1 (0.35) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL1786337 0.80 ALDH1A1 (0.31) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL18203204 0.80 ALDH1A1 (0.35) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL1786335 0.80 ALDH1A1 (0.31) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL3898173 0.78 CYP2D6 (0.50) ALDH1A1TSHRACLYCYP2D6CYP2C19
SCHEMBL21292006 0.78 FFAR1 (0.30) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL21292007 0.78 FFAR1 (0.30) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL3898176 0.78 CYP2D6 (0.50) ALDH1A1TSHRACLYCYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170239212-A1 BRYOSTATIN ANALOGS AND USE THEREOF AS ANTIVIRAL AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-08-24 US disclosed
EP-0293053-B1 PROCESS FOR THE PREPARATION OF CYCLIC CARBOXYLIC ANHYDRIDES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1992-03-04 EP disclosed
EP-0293053-A2 Process for the preparation of cyclic carboxylic anhydrides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239212-A1 BRYOSTATIN ANALOGS AND USE THEREOF AS ANTIVIRAL AGENTS PRKCH, PRKCZ, PRKCB ALDH1A1 4871/4885CYP19A1 4534/4885MAPT 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.